Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10454564 | 0.86 | SMN1; SMN2 (0.34) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL10455692 | 0.83 | ALDH1A1 (0.37) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL2098816 | 0.83 | ALDH1A1 (0.43) | CA12CA1CA2ALDH1A1TDP1 | |
| SCHEMBL10454575 | 0.82 | CA1 (0.34) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL27281375 | 0.80 | ALDH1A1 (0.40) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL10454757 | 0.80 | ALDH1A1 (0.34) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL16610683 | 0.79 | CA1 (0.39) | CA12CA1CA2CA9MGAM | |
| SCHEMBL25457592 | 0.79 | ALDH1A1 (0.40) | CA12CA1CA2ALDH1A1TDP1 | |
| SCHEMBL6311749 | 0.73 | CA2 (0.52) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL8537199 | 0.73 | KMT2A (0.62) | ALDH1A1TDP1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0245315-B1 | PROCESS FOR PREPARING $g(a)-HYDROXY CARBONYL COMPOUNDS | L. GIVAUDAN & CIE Société Anonyme (CH) | 1990-04-11 | — | — | EP | claimed |
| US-4892966-A | FLAVORS FOR FOODS, TOBACCO | GIVAUDAN CORPORATION (US) | 1990-01-09 | — | — | US | claimed |
| EP-0245315-A1 | PROCESS FOR PREPARING -g(a)-HYDROXY CARBONYL COMPOUNDS. | GIVAUDAN & CIE SA (CH) | 1987-11-19 | — | — | EP | claimed |
| WO-1987003287-A2 | PROCESS FOR PREPARING alpha-HYDROXY CARBONYL COMPOUNDS | L. GIVAUDAN & CIE SOCIETE ANONYME (CH) | 1987-06-04 | — | — | WO | claimed |
| US-7829586-B2 | Aryl-substituted nitrogen-containing heterocyclic compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | MSD K.K. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1935881-A1 | ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-0245315-B1 | PROCESS FOR PREPARING $g(a)-HYDROXY CARBONYL COMPOUNDS | L. GIVAUDAN & CIE Société Anonyme (CH) | 1990-04-11 | — | — | EP | disclosed |
| US-4892966-A | FLAVORS FOR FOODS, TOBACCO | GIVAUDAN CORPORATION (US) | 1990-01-09 | — | — | US | disclosed |
| EP-0245315-A1 | PROCESS FOR PREPARING -g(a)-HYDROXY CARBONYL COMPOUNDS. | GIVAUDAN & CIE SA (CH) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | OPRL1, NPSR1, NPBWR1 | CA12 3951/4885CA1 3211/4885CA2 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.